Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2026, Vol. 58 ›› Issue (2): 431-435. doi: 10.19723/j.issn.1671-167X.2026.02.032

Previous Articles    

Research progress in clinical pathology and molecular mechanisms of pancreatic adenosquamous carcinoma

Zichen PAN1, Kai CHEN1, Yukun HOU1, Bohan YANG1, Jixin ZHANG2, Yongsu MA1, Xiaodong TIAN1,*(), Yinmo YANG1,*()   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China
    2. Department of Pathology, Peking University First Hospital, Beijing 100034, China
  • Received:2026-01-07 Online:2026-04-18 Published:2026-02-05
  • Contact: Xiaodong TIAN, Yinmo YANG
  • Supported by:
    the National Natural Science Foundation of China(82541012); the National Natural Science Foundation of China(82571996)

RICH HTML

   

PDF (PC)

Abstract:

Pancreatic adenosquamous carcinoma (PASC) is a rare exocrine malignancy of the pancreas with an increasing incidence, histologically defined by the coexistence of adenocarcinoma and squamous carcinoma components. Current pathological diagnosis typically requires the squamous component to comprise at least 30% of the tumor. However, this threshold remains controversial given the unconfirmed independent prognostic value of the extent of squamous differentiation. Compared with pancreatic ductal adenocarcinoma (PDAC), PASC exhibits greater aggressiveness and heterogeneity, contributing to a poorer prognosis with a median survival of approximately 9 months. Despite its distinct biological behavior, specific preoperative diagnostic methods and targeted therapeutic strategies remain elusive. Diagnostically, while PASC lacks specific molecular markers, the ring-enhancement sign observed in the arterial phase of contrast-enhanced CT may aid distinction from PDAC. Owing to the lack of standardized therapeutic strategies, treatment largely follows guidelines established for PDAC, offering limited survival benefits, though platinum-based chemotherapy and radiotherapy show potential efficacy. Notably, the rationale for immunotherapy lies in the high programmed death-ligand 1 (PD-L1) expression in the squamous component and an immunosuppressive microenvironment characterized by specific checkpoint interactions, such as the TIGIT-CD155 axis. Furthermore, the cellular origin and evolutionary trajectory of PASC remain debated. While monoclonal origin is the prevailing theory, it remains unclear whether the squamous component arises from adenocarcinoma transdifferentiation or from pancreatic pluripotent stem cells. At the molecular level, PASC shares genomic and transcriptomic features with PDAC yet maintains a distinct identity. Concurrently, its tumor microenvironment (TME) displays unique landscapes, differing significantly from PDAC in immune and stromal components like T cells, macrophages, and fibroblasts. Moreover, marked intratumoral heterogeneity is observed between the adenocarcinoma and squamous carcinoma regions within the same tumor. Future efforts should prioritize multi-omics and laser microdissection technologies to establish a refined molecular classification system, alongside the integration of liquid biopsy and artificial intelligence (AI)-assisted radiomics for accurate preoperative diagnosis. This comprehensive strategy is essential to shift clinical practice from empirical treatment to personalized precision medicine, ultimately improving outcomes for this refractory disease. This article systematically reviews the epidemiology and clinicopathological features of PASC, and specifically explores the therapeutic potential of platinum-based chemotherapy, radiotherapy, and immunotherapy. Furthermore, special attention is given to recent advances in monoclonal origin patterns, unique genomic and transcriptomic alterations, and TME heterogeneity.

Key words: Pancreatic adenosquamous carcinoma, Epidemiology, Immunotherapy, Multi-omics, Molecular typing

CLC Number: 

  • R735.9
1
Bray F , Laversanne M , Sung H , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74 (3): 229- 263.
2
Siegel RL , Kratzer TB , Giaquinto AN , et al. Cancer statistics, 2025[J]. CA Cancer J Clin, 2025, 75 (1): 10- 45.
3
Wu Z , Fang Z , Zeng L , et al. RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway[J]. Theranostics, 2025, 15 (17): 9261- 9278.

doi: 10.7150/thno.112753
4
World Health Organization . International agency for research on cancer. Digestive system tumours[M]. 5th ed Lyon: International Agency for Research on Cancer, 2019.
5
Braun R , Klinkhammer-Schalke M , Zeissig SR , et al. Clinical outcome and prognostic factors of pancreatic adenosquamous carcinoma compared to ductal adenocarcinoma-results from the German Cancer Registry Group[J]. Cancers (Basel), 2022, 14 (16): 3946.

doi: 10.3390/cancers14163946
6
Huang Z , Wang J , Zhang R , et al. Pancreatic adenosquamous carcinoma: A population level analysis of epidemiological trends and prognosis[J]. Cancer Med, 2023, 12 (8): 9926- 9936.

doi: 10.1002/cam4.5700
7
Imaoka H , Shimizu Y , Mizuno N , et al. Clinical characteristics of adenosquamous carcinoma of the pancreas: A matched case-control study[J]. Pancreas, 2014, 43 (2): 287- 290.

doi: 10.1097/MPA.0000000000000089
8
Sakakida T , Ishikawa T , Doi T , et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: Analysis with the national database of Japan[J]. J Gastroenterol, 2023, 58 (6): 575- 585.

doi: 10.1007/s00535-023-01986-9
9
Satake T , Morizane C , Rikitake R , et al. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry[J]. J Gastroenterol, 2022, 57 (11): 890- 901.

doi: 10.1007/s00535-022-01920-5
10
Hester CA , Augustine MM , Choti MA , et al. Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database[J]. J Surg Oncol, 2018, 118 (1): 21- 30.

doi: 10.1002/jso.25112
11
Boyd CA , Benarroch-Gampel J , Sheffield KM , et al. 415 patients with adenosquamous carcinoma of the pancreas: A population-based analysis of prognosis and survival[J]. J Surg Res, 2012, 174 (1): 12- 19.

doi: 10.1016/j.jss.2011.06.015
12
Su W , Zhao S , Chen Y , et al. (18)F-FDG PET/CT feature of pancreatic adenosquamous carcinoma with pathological correlation[J]. Abdom Radiol (NY), 2020, 45 (3): 743- 749.

doi: 10.1007/s00261-019-02393-6
13
Lee SM , Sung CO . PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions[J]. Pancreatology, 2021, 21 (5): 920- 927.

doi: 10.1016/j.pan.2021.03.004
14
Zhang W , Zhang J , Liang X , et al. Research advances and treatment perspectives of pancreatic adenosquamous carcinoma[J]. Cell Oncol (Dordr), 2023, 46 (1): 1- 15.
15
Voong KR , Davison J , Pawlik TM , et al. Resected pancreatic adenosquamous carcinoma: Clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients[J]. Hum Pathol, 2010, 41 (1): 113- 122.

doi: 10.1016/j.humpath.2009.07.012
16
Kardon DE , Thompson LD , Przygodzki RM , et al. Adenosquamous carcinoma of the pancreas: A clinicopathologic series of 25 cases[J]. Mod Pathol, 2001, 14 (5): 443- 451.

doi: 10.1038/modpathol.3880332
17
Murakami Y , Yokoyama T , Yokoyama Y , et al. Adenosquamous carcinoma of the pancreas: Preoperative diagnosis and molecular alterations[J]. J Gastroenterol, 2003, 38 (12): 1171- 1175.

doi: 10.1007/s00535-003-1226-4
18
Inoue T , Nagao S , Tajima H , et al. Adenosquamous pancreatic cancer producing parathyroid hormone-related protein[J]. J Gastroenterol, 2004, 39 (2): 176- 180.

doi: 10.1007/s00535-003-1270-0
19
Kobayashi N , Higurashi T , Iida H , et al. Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM)[J]. J Hepatobiliary Pancreat Surg, 2008, 15 (5): 531- 535.

doi: 10.1007/s00534-007-1258-x
20
Bachmeyer C , Canard A , Wendum D , et al. Recent-onset diabetes mellitus and paraneoplastic hypercalcemia revealing adenosquamous carcinoma of the pancreas[J]. Am J Med, 2023, 136 (8): e157- e158.

doi: 10.1016/j.amjmed.2023.03.031
21
Liu C , Karam R , Zhou Y , et al. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma[J]. Nat Med, 2014, 20 (6): 596- 598.

doi: 10.1038/nm.3548
22
Lenkiewicz E , Malasi S , Hogenson TL , et al. Genomic and epigenomic landscaping defines new therapeutic targets for adenosquamous carcinoma of the pancreas[J]. Cancer Res, 2020, 80 (20): 4324- 4334.

doi: 10.1158/0008-5472.CAN-20-0078
23
Imaoka H , Shimizu Y , Mizuno N , et al. Ring-enhancement pattern on contrast-enhanced CT predicts adenosquamous carcinoma of the pancreas: A matched case-control study[J]. Pancreatology, 2014, 14 (3): 221- 226.

doi: 10.1016/j.pan.2014.02.005
24
Kuji I , Sumiya H , Taki J , et al. Intense Ga-67 uptake in adenosquamous carcinoma of the pancreas[J]. Ann Nucl Med, 1997, 11 (1): 41- 43.

doi: 10.1007/BF03164758
25
Hue JJ , Katayama E , Sugumar K , et al. The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: Analysis of treatment sequence and strategy[J]. Surgery, 2021, 169 (5): 1102- 1109.

doi: 10.1016/j.surg.2020.11.026
26
Smoot RL , Zhang L , Sebo TJ , et al. Adenosquamous carcinoma of the pancreas: A single-institution experience comparing resection and palliative care[J]. J Am Coll Surg, 2008, 207 (3): 368- 370.

doi: 10.1016/j.jamcollsurg.2008.03.027
27
Wild AT , Dholakia AS , Fan KY , et al. Efficacy of platinum che-motherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas[J]. J Gastrointest Oncol, 2015, 6 (2): 115- 125.
28
Fang Y , Pu N , Zhang L , et al. Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma: A retrospective cohort study from the SEER database[J]. Ann Transl Med, 2019, 7 (20): 522.

doi: 10.21037/atm.2019.10.12
29
Lv SY , Lin MJ , Yang ZQ , et al. Survival analysis and prediction model of ASCP based on SEER database[J]. Front Oncol, 2022, 12, 909257.

doi: 10.3389/fonc.2022.909257
30
Tanigawa M , Naito Y , Akiba J , et al. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component[J]. Pathol Res Pract, 2018, 214 (12): 2069- 2074.

doi: 10.1016/j.prp.2018.10.006
31
Chen X , Sun S , Li S , et al. Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception[J]. J Immunother Cancer, 2025, 13 (6): e012066.

doi: 10.1136/jitc-2025-012066
32
Chen X , Sun S , Li S , et al. Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma[J]. Eur J Cancer, 2025, 232, 116159.
33
Motojima K , Tomioka T , Kohara N , et al. Immunohistochemical characteristics of adenosquamous carcinoma of the pancreas[J]. J Surg Oncol, 1992, 49 (1): 58- 62.

doi: 10.1002/jso.2930490114
34
Fang Y , Su Z , Xie J , et al. Genomic signatures of pancreatic adenosquamous carcinoma (PASC)[J]. J Pathol, 2017, 243 (2): 155- 159.

doi: 10.1002/path.4943
35
Makiyama K , Takuma K , Zea-Iriarte WL , et al. Adenosquamous carcinoma of the pancreas[J]. J Gastroenterol, 1995, 30 (6): 798- 802.

doi: 10.1007/BF02349652
36
Boecker W , Tiemann K , Boecker J , et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: Evidence supporting the squamous metaplasia concept[J]. Histochem Cell Biol, 2020, 154 (1): 97- 105.

doi: 10.1007/s00418-020-01864-y
37
Ishikawa O , Matsui Y , Aoki I , et al. Adenosquamous carcinoma of the pancreas: A clinicopathologic study and report of three cases[J]. Cancer, 1980, 46 (5): 1192- 1196.

doi: 10.1002/1097-0142(19800901)46:5<1192::AID-CNCR2820460519>3.0.CO;2-D
38
Hamdan FH , Johnsen SA . DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network[J]. Proc Natl Acad Sci USA, 2018, 115 (52): e12343- e12352.
39
Somerville TDD , Xu Y , Miyabayashi K , et al. TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma[J]. Cell Rep, 2018, 25 (7): 1741- 1755.e7.

doi: 10.1016/j.celrep.2018.10.051
40
Rajbhandari N , Hamilton M , Quintero CM , et al. Single-cell mapping identifies MSI(+) cells as a common origin for diverse subtypes of pancreatic cancer[J]. Cancer Cell, 2023, 41 (11): 1989- 2005.e9.

doi: 10.1016/j.ccell.2023.09.008
41
Zhao X , Li H , Lyu S , et al. Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma[J]. Int J Biol Sci, 2021, 17 (10): 2590- 2605.

doi: 10.7150/ijbs.58886
42
Jiang Y , Wu Y , Zhang L , et al. Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas[J]. Precis Clin Med, 2023, 6 (4): pbad030.

doi: 10.1093/pcmedi/pbad030
43
Kania BE , Baca Y , Riedlinger G , et al. Genomics and transcriptomics of pancreatic adenosquamous carcinoma[J]. J Clin Oncol, 2024, 42 (Suppl 3): 691.
44
Yang D , Sun X , Moniruzzaman R , et al. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation[J]. Cell Rep Med, 2024, 5 (9): 101711.

doi: 10.1016/j.xcrm.2024.101711
45
陈立新. 胰腺腺鳞癌的临床病理学特征、驱动基因变异及免疫微环境研究[D]. 北京: 北京协和医学院, 2025.
46
Zhang D , Wu S , Pan S , et al. Single-cell sequencing reveals heterogeneity between pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma with prognostic value[J]. Front Immunol, 2022, 13, 972298.

doi: 10.3389/fimmu.2022.972298
47
Somerville TD , Biffi G , Daβler-Plenker J , et al. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation[J]. eLife, 2020, 9, e53381.

doi: 10.7554/eLife.53381
[1] Hao FU, Luyan SHEN, Bingyang HUANG, Shaohua MA. Clinical strategies for perioperative management of esophageal squamous cell carcinoma in the immunotherapy era [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 266-271.
[2] Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[3] Junjie HUANG, Zhaorui LIU, Tingting ZHANG, Yueqin HUANG. Cross-century process of mental health surveys in China [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 868-874.
[4] Zhemin LI, Jiafu JI, Guoxin LI, Ziyu LI, Zhaode BU, Xiangyu GAO, Di DONG, Lei TANG, Xiaofang XING, Shuqin JIA, Ting GUO, Lianhai ZHANG, Fei SHAN, Xin JI, Anqiang WANG. Development and dissemination of precision medicine approaches in gastric cancer management [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 864-867.
[5] Jiaxin NING, Haoran WANG, Shuhang LUO, Jibo JING, Jianye WANG, Huimin HOU, Ming LIU. Multi-omics analysis of the relationship between oxidative stress-related gene and prostate cancer [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 633-643.
[6] Xin CHEN, Junting YANG, Jinxin GUO, Shuya LI, Zhike LIU, Yingliang ZHU, Fengjuan LI, Siyan ZHAN, Juanjuan GUO. Prevalence characteristics of autoimmune thyroid disease in women aged 10-59 years in Qingdao City from 2022 to 2024 [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 507-513.
[7] Xuejun LIANG, Fengxia ZHANG, Ting JIN, Jingjing ZHU. Biological activity and antitumor effect of long-acting recombinant human interleukin-2 drug [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 253-261.
[8] Jiajun LIU, Guokang LIU, Yuhu ZHU. Immune-related severe pneumonia: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 932-937.
[9] Zi-kai WANG,Jia-li MO,Meng ZHANG,Ji-ping LIAO. Epidemiology and hospitalization costs analysis of female inpatients with acute exacerbation of chronic obstructive pulmonary disease in Beijing from 2013 to 2020 [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1074-1081.
[10] Zhe WANG,Wei SUN,Xue YANG,Ying SONG,Ai-ping JI,Jie BAI. Clinical analysis of patients with oral and maxillofacial infections in oral emergency [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 543-547.
[11] Si-wei DENG,Ze-yi CHEN,Zhi-ke LIU,Jian WANG,Lin ZHUO,Shuang-qing GAO,Jia-kuo YU,Si-yan ZHAN. Epidemiological study of bone and joint injury based on urban medical insurance database [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 527-534.
[12] Li-jun ZHAO,Hong-tian LI,Ya-li ZHANG,Yu-bo ZHOU,Jian-meng LIU. Mobile terminal-based survey on the birth characteristics for Chinese newborns [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 813-818.
[13] LIU Jing-wei, LU Xu, YANG Zhao-min, DENG Li-juan, YANG Lin. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 840-846.
[14] YE Hai-yun, XU Qing-quan, HUANG Xiao-bo, MA Kai, WANG Xiao-feng. Tuberculous prostatic abscess following intravesical bacillus Calmette-Guérin immunotherapy: a case report [J]. Journal of Peking University(Health Sciences), 2015, 47(6): 1039-1041.
[15] XIAO Zong-Yu, CHEN Xiao-Juan, YANG Yi, XU Ru-Xiang. Experimental study of dendritic cells transfected with cancer stem like cells RNA against 9L brain tumors [J]. Journal of Peking University(Health Sciences), 2015, 47(4): 661-666.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd